Citation
Circulating Markers of Cardiovascular Health in Hypogonadism Before and After Testosterone Therapy: Molecular Aspects and Formulation Comparison
La Vignera S, Condorelli RA.
Int J Mol Sci. 2026;27(13). Published July 5, 2026.
PMID: 42450305 DOI: 10.3390/ijms27136035
Study at a Glance
- Design
- Narrative review
1. Question Addressed
Which blood markers of vascular repair, injury, and inflammation differ in men with hypogonadism, and how do they change during testosterone therapy? Does the evidence establish a cardiovascular safety advantage for skin preparations or injections?
2. Plain Language Summary
Blood vessels continually repair their inner lining. Men with low testosterone often had fewer circulating cells involved in this repair and more small particles shed by injured vessel walls. In a small study, repair-cell counts rose during a year of testosterone gel use. Whether this change lowers a man’s chance of a heart attack or stroke remains unknown [2,3].
The clearest difference between preparations concerned hematocrit, the percentage of blood volume occupied by red blood cells. In a registry, hematocrit exceeded 50% in about 23 of every 100 men using long-acting injections and 5 of every 100 using gel. A large randomized trial found similar rates of major cardiovascular events with gel and placebo. It had no injection group, so the relative safety of the 2 preparations remains uncertain [4,5].
3. Study at a Glance
- Design and population. Narrative review of experimental research and clinical studies in men with hypogonadism. Each clinical study had its own sample, age range, and follow-up.
- Sources and period. The authors cite laboratory studies, clinical cohorts, registries, randomized trials, and reviews. They give no database list, search dates, or formal evidence grades.
- Exposures and outcomes. Untreated hypogonadism, transdermal testosterone, and intramuscular testosterone. Outcomes included vascular biomarkers, hematocrit, and clinical cardiovascular events.
4. Methods
The authors organized the literature by biological pathway and formulation. They described the direction of changes across studies without pooling effect estimates or applying a formal risk-of-bias assessment (La Vignera and Condorelli 2026).
- Mechanistic studies. Cell and animal experiments examined how testosterone affects nitric oxide production, inflammatory signaling, and the release of progenitor cells from bone marrow.
- Clinical biomarker studies. Investigators compared men with hypogonadism with controls or repeated measurements after treatment. Studies differed in how they identified progenitor cells and measured vascular injury.
- Formulation comparisons. Registry data addressed hematocrit during gel or injection use. The randomized TRAVERSE trial compared daily gel with placebo in 5,246 men aged 45 to 80 years with cardiovascular disease or elevated cardiovascular risk.
5. Key Findings
- Vascular repair. Among 29 men prescribed gel, mean circulating endothelial progenitor cell counts rose from 9.5 at baseline to 16.6 at 3 months (p = 0.027), 20.3 at 6 months (p = 0.006), and 27.2 at 12 months (p = 0.017) per 100,000 monocytes. A separate cohort of 22 men with Klinefelter syndrome had no significant increase after 6 months (Liao et al. 2013, La Vignera and Condorelli 2026).
- Endothelial injury and inflammation. Some studies found fewer endothelial microparticles or lower adhesion molecule levels after treatment. Evidence for microparticles was limited. Changes in high-sensitivity C-reactive protein and inflammatory cytokines varied, and platelet responses depended in part on dose (La Vignera and Condorelli 2026).
- Hematocrit. At 26 to 30 weeks, hematocrit exceeded 50% in 69/304 men receiving intramuscular testosterone undecanoate (22.7%) and 25/498 using gel (5.0%, p < 0.001). Older age, greater waist circumference, and a larger testosterone increase also predicted hematocrit response (Zitzmann et al. 2022).
- Cardiovascular events. Over a mean 33 months, cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 7.0% with gel and 7.3% with placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17, p < 0.001 for noninferiority). Atrial fibrillation, acute kidney injury, and pulmonary embolism occurred more often with gel (Lincoff et al. 2023).
6. Limitations and Strengths Affecting Interpretation
Strengths
- Biological detail. The review connects specific markers with distinct processes, including nitric oxide production in the vessel wall, cell recruitment for repair, and stimulation of red blood cell production.
- Clinical comparisons. The evidence tables identify the population, preparation, duration, and outcomes of individual studies, including findings that differed by cause of hypogonadism.
Limitations
- Study selection. The review gives no reproducible search, eligibility criteria, or formal grading method. Readers cannot assess how completely it represents the evidence.
- Measurement and confounding. Small cohorts used different marker definitions. Obesity, diabetes, and underlying cardiovascular disease may influence both testosterone and vascular measures.
- Clinical endpoints. The review identified no randomized head-to-head trial powered to compare cardiovascular events with transdermal and intramuscular treatment.
The hematocrit findings can inform monitoring and discussions about formulation. Changes in progenitor cells or inflammatory markers cannot establish that either preparation prevents cardiovascular events (La Vignera and Condorelli 2026, Zitzmann et al. 2022).
7. Authors’ Conclusions
The authors concluded that hypogonadism is associated with impaired vascular repair and signs of endothelial injury, and that several markers improve during testosterone replacement. They considered steadier hormone exposure and a lower frequency of erythrocytosis potential advantages of transdermal therapy. They called for direct randomized comparisons to determine whether those differences affect cardiovascular outcomes (La Vignera and Condorelli 2026).
8. Commentary
This review extends the clinical literature by bringing vascular repair, endothelial injury, inflammation, and formulation-specific hematologic effects into a single discussion. Its mechanistic explanations help interpret the rise in endothelial progenitor cells reported in a small prospective study of testosterone gel. That study followed 29 treated men for 12 months and found progressively higher cell counts. The review also describes a cohort with Klinefelter syndrome in which counts did not increase significantly, indicating that responses may differ according to the underlying cause of hypogonadism (Liao et al. 2013, La Vignera and Condorelli 2026).
The contribution of this review is its integration of biological pathways with clinical observations. Testosterone can influence nitric oxide signaling, inflammatory pathways, and recruitment of cells involved in endothelial repair. These mechanisms provide plausible explanations for changes in circulating markers. Establishing their clinical significance would require evidence linking treatment-related marker changes to subsequent cardiovascular outcomes. The reviewed studies leave that relationship unresolved, and the authors provide no validated progenitor-cell or microparticle targets for selecting a dose or assessing treatment success (La Vignera and Condorelli 2026).
For clinicians comparing formulations, hematocrit provides a directly actionable measure. In the HEAT Registry, hematocrit exceeded 50% in 69 of 304 men receiving long-acting intramuscular testosterone undecanoate and 25 of 498 men using gel after approximately 6 months. Older age, greater waist circumference, and larger increases in testosterone also contributed to the hematocrit response. These associations support considering both the preparation and the individual patient’s characteristics when planning follow-up and discussing treatment options (Zitzmann et al. 2022).
The Endocrine Society guideline recommends measuring hematocrit before treatment, at 3 to 6 months, and annually thereafter. A hematocrit above 54% warrants withholding treatment, evaluating for hypoxia and sleep apnea, and resuming therapy at a reduced dose once hematocrit has returned to a safe level. The registry’s 50% threshold therefore identifies an earlier hematologic response than the guideline’s treatment-interruption threshold. Applying the registry findings requires attention to the threshold used and to the patient’s serial measurements (Bhasin et al. 2018, Zitzmann et al. 2022).
TRAVERSE supplies clinical outcome evidence relevant to the review’s discussion of cardiovascular safety. Among 5,246 men with hypogonadism and established cardiovascular disease or increased cardiovascular risk, dose-adjusted testosterone gel met the prespecified noninferiority criterion for major adverse cardiovascular events compared with placebo. Mean follow-up was 33 months. The higher incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group remain relevant to the overall safety assessment. Because the trial had no injection arm, it cannot determine comparative cardiovascular event rates for gel and injections (Lincoff et al. 2023).
This review should be interpreted as a mechanistic synthesis supporting individualized formulation choice and guideline-based hematocrit monitoring in clinical practice, with comparative cardiovascular event benefits remaining unproven pending direct randomized trials (La Vignera and Condorelli 2026, Bhasin et al. 2018, Zitzmann et al. 2022).
9. References
1. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
DOI 10.1210/jc.2018-00229 | PubMed 29562364
Supporting quote: “Check hematocrit at baseline, 3–6 mo after starting treatment, and then annually.”
2. La Vignera S, Condorelli RA. Circulating Markers of Cardiovascular Health in Hypogonadism Before and After Testosterone Therapy: Molecular Aspects and Formulation Comparison. Int J Mol Sci. 2026;27(13):6035.
DOI 10.3390/ijms27136035 | PubMed 42450305
Supporting quote: “direct comparative evidence from randomized trials with hard cardiovascular endpoints remains unavailable.”
3. Liao CH, Wu YN, Lin FY, Tsai WK, Liu SP, Chiang HS. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism. Andrology. 2013;1(4):563–569.
DOI 10.1111/j.2047-2927.2013.00086.x | PubMed 23653307
Supporting quote: “the number was significantly higher after 3 months”
4. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al.; TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117.
DOI 10.1056/NEJMoa2215025 | PubMed 37326322
Supporting quote: “testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events.”
5. Zitzmann M, Cremers JF, Krallmann C, Kliesch S. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men. Aging Male. 2022;25(1):134–144.
DOI 10.1080/13685538.2022.2063830 | PubMed 35467476
Supporting quote: “69/304 vs. 25/498, p < 0.001”